7M42

Complex of SARS-CoV-2 receptor binding domain with the Fab fragments of neutralizing antibodies REGN10985 and REGN10989

Summary for 7M42

• Entry DOI: 10.2210/pdb7m42/pdb
• EMDB information: 23662
• Descriptor: REGN10989 antibody Fab fragment light chain, REGN10989 antibody Fab fragment heavy chain, Spike protein S1, ... (6 entities in total)
• Functional Keywords: sars-cov-2, rbd, neutralizing antibody, viral protein-immune system complex, viral protein/immune system
• Biological source: Homo sapiens (Human); More
• Total number of polymer chains: 5
• Total formula weight: 124303.24

Authors

Zhou, Y.,Romero Hernandez, A.,Saotome, K.,Franklin, M.C. (deposition date: 2021-03-19, release date: 2021-07-28, Last modification date: 2024-11-20)

Primary citation

Copin, R.,Baum, A.,Wloga, E.,Pascal, K.E.,Giordano, S.,Fulton, B.O.,Zhou, A.,Negron, N.,Lanza, K.,Chan, N.,Coppola, A.,Chiu, J.,Ni, M.,Wei, Y.,Atwal, G.S.,Hernandez, A.R.,Saotome, K.,Zhou, Y.,Franklin, M.C.,Hooper, A.T.,McCarthy, S.,Hamon, S.,Hamilton, J.D.,Staples, H.M.,Alfson, K.,Carrion Jr., R.,Ali, S.,Norton, T.,Somersan-Karakaya, S.,Sivapalasingam, S.,Herman, G.A.,Weinreich, D.M.,Lipsich, L.,Stahl, N.,Murphy, A.J.,Yancopoulos, G.D.,Kyratsous, C.A.
The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.
Cell, 184:3949-, 2021

PubMed Abstract: Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19. Because rapidly emerging virus mutants are becoming the next major concern in the fight against the global pandemic, it is imperative that these therapeutic treatments provide coverage against circulating variants and do not contribute to development of treatment-induced emergent resistance. To this end, we investigated the sequence diversity of the spike protein and monitored emergence of virus variants in SARS-COV-2 isolates found in COVID-19 patients treated with the two-antibody combination REGEN-COV, as well as in preclinical in vitro studies using single, dual, or triple antibody combinations, and in hamster in vivo studies using REGEN-COV or single monoclonal antibody treatments. Our study demonstrates that the combination of non-competing antibodies in REGEN-COV provides protection against all current SARS-CoV-2 variants of concern/interest and also protects against emergence of new variants and their potential seeding into the population in a clinical setting.

PubMed: 34161776
DOI: 10.1016/j.cell.2021.06.002

Experimental method

ELECTRON MICROSCOPY (3.3 Å)